Physician profile
David Wallace
NPI 1730852179
$4,450.41
in general payments reported to CMS, 2019-2025
31 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.61 · 2022: $710 · 2023: $881 · 2024: $1,411 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $731.24 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $578.15 | 2022-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $405.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $343.19 | 2021-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $322.40 | 2022-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $215.62 | 2024-2025 | Voquezna |
| Genzyme Corporation | $199.71 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $181.48 | 2022-2025 | Entyvio, Trintellix |
| Pfizer INC. | $151.74 | 2024-2025 | |
| Ardelyx, INC. | $149.02 | 2022-2024 | Ibsrela |
| Braintree Laboratories, INC. | $131.91 | 2021-2023 | Sutab, Suflave |
| Alkermes, INC. | $100.00 | 2022 | |
| Exact Sciences Corporation | $82.45 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $78.82 | 2024 | Omvoh |
| Lundbeck LLC | $74.91 | 2025 | Rexulti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $74.62 | 2025 | Loreev Xr |
| Qol Medical, LLC | $72.46 | 2025 | Sucraid |
| Otsuka America Pharmaceutical, INC. | $67.63 | 2022-2025 | Rexulti |
| Bausch Health US, LLC | $59.75 | 2023-2025 | Aplenzin |
| Celgene Corporation | $58.48 | 2022-2023 | Zeposia |
| Lucid Diagnostics INC. | $51.59 | 2022-2024 | |
| Vanda Pharmaceuticals INC. | $51.49 | 2022 | |
| Novo Nordisk INC | $44.33 | 2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.02 | 2024-2025 | Caplyta |
| Fujifilm Healthcare Americas Corporation | $35.00 | 2024 | Utaswako Afp-L3 |
| Aimmune Therapeutics, INC. | $33.57 | 2024 | |
| Janssen Biotech, INC. | $31.54 | 2025 | Simponi, Simponi Aria, Stelara |
| Axsome Therapeutics, INC. | $27.68 | 2025 | Auvelity |
| Ipsen Biopharmaceuticals, INC | $25.78 | 2025 | Iqirvo |
| Mirum Pharmaceuticals, INC. | $21.83 | 2024 | Livmarli |
| Redhill Biopharma INC. | $13.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.